Orexo Added to Russell Global Index

| Source: Orexo AB
Uppsala, Sweden – June 30, 2014 – Orexo AB (NASDAQ OMX Stockholm: ORX and US
OTCQX: ORXOY) today announced that the Company’s stock has been added to the
Russell Global Index. The inclusion is part of the annual reconstitution of the
entire Russell family of indexes that took place on June 27, 2014, following the
close of market.

“Being added to this global index is a reflection of the progress Orexo has made
within the last year and should help to increase the Company’s visibility
internationally, particularly in the US,” said Nikolaj Sørensen, President and
CEO of Orexo.

The Russell Global Indexes reflect the performance of over 10,000 securities in
47 countries.

Selection for inclusion in these indexes is based upon market capitalization and
other market factors relating to a company and its stock. Membership in these
indexes is updated annually, and remains in place for one year.

Russell Indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies.
Approximately $5.2 trillion in assets currently are benchmarked to Russell

For further information, please contact:
Henrik Juuel, EVP and CFO
Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com

About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery technology and commercial operations in the United States. The company
is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for
maintenance treatment of opioid dependence, in the United States. The ZUBSOLV®
sublingual tablet is a novel formulation of buprenorphine and naloxone using
Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of
two approved and revenue generating products currently marketed under license in
the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ
OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the
OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest
shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 08:30am CET on June 30, 2014.